ENVX

Enovix is a pre-commercial battery developer whose financials don't yet support its $1.33B market cap. FY2025 revenue of just $31.8M (+37.9%) against a -$157M net loss values the equity at 41.6x sales, a price that only makes sense if you fully underwrite the silicon-anode AI-1 platform reaching scaled commercialization. The MD&A is candid that the company has 'concentrated operational efforts on researching, developing and commercializing' its architecture and that its biggest real revenue today is conventional/defense product — 'naval munitions being our top product in the fourth quarter' — not the silicon-anode smartphone/eyewear story the multiple is paying for. A gross margin that just turned positive (19.2%) on $31.8M of sales is encouraging but trivial against $110M of R&D and a -557% operating margin.

The balance sheet is moving the wrong way at precisely the moment the company needs runway. Cash fell 61.1% to $106M while long-term debt ballooned 205.8% to $519M, pushing liabilities/equity to 2.23x and retained-earnings deficit to -$978M. Operating cash flow was -$95.3M; at that burn, the $106M cash position is roughly one year of runway, which all but guarantees further debt or equity raises — shares already grew 13.6% in FY2025. Spending $58.4M on buybacks while burning cash and diluting is a confusing capital-allocation signal. The improving net-loss trend (from -$222M to -$157M) is genuine progress, but the company is still years and a lot of external capital away from self-funding.